Group 1 - The company is steadily advancing its "smart hospital" construction [1] - The company continues to pay attention to new developments in cutting-edge interdisciplinary fields [1]

Group 1 - The company has continued to provide high-quality ophthalmic medical services and has become the only center in Hong Kong offering a comprehensive advanced refractive treatment product portfolio, including LASIK, SMILE, SMILE Pro, SILKTM, and ICL, solidifying its technological leadership in the market [1] - The company's business performance has remained stable, with a gradual recovery in operational performance by the end of 2025, as evidenced by patient visits, new patient appointments, and surgical volumes reaching or exceeding levels from the same period in the past two years [1] - The company ranked first in Hong Kong for ICL surgeries in 2025, achieving the industry's top position for the third consecutive year [1] Group 2 - The company has incurred significant professional fees exceeding HKD 15 million due to ongoing allegations against former directors, which have created a substantial financial burden that could have been allocated to business development and enhancing shareholder returns [1] - The company is committed to efficiently completing the investigation related to the allegations and accelerating the resumption of its shares, allowing management to refocus on executing its long-term strategic priorities [1] - The latest resumption guidance includes various directives such as investigation and rectification guidelines, integrity guidelines, internal control guidelines, corporate governance guidelines, disclosure guidelines, financial reporting guidelines, and compliance with Article 13.24 [2]

Core Viewpoint - Clear Medical (01406.HK) has established itself as the only ophthalmic center in Hong Kong offering a comprehensive advanced refractive treatment portfolio, solidifying its technological leadership in the market [1] Group 1: Company Performance - The company has continued to provide high-quality ophthalmic medical services over the past few months [1] - After a period of slightly weak performance, operational metrics began to recover by the end of 2025, with December seeing patient visits, new patient appointments, and surgical volumes reaching or exceeding levels from the same period in the past two years [1] - The company ranked first in Hong Kong for ICL surgeries in 2025, marking its third consecutive year as the industry leader [1] Group 2: Strategic Developments - The company is set to officially launch the SILK refractive surgery platform in collaboration with Johnson & Johnson in November 2025 [1] - The introduction of the SILK platform enhances the company's offerings, which include LASIK, SMILE, SMILEPro, SILKTM, and ICL [1]

Group 1 - The core viewpoint of the article highlights that Clear Medical (01406) has established itself as the only ophthalmic center in Hong Kong offering a comprehensive advanced refractive treatment product portfolio, further solidifying its technological leadership in the market [1] - The company's business performance has shown resilience, with patient visits, new patient appointments, and surgical volumes in December 2025 reaching or exceeding levels from the same period in the past two years [1] - Clear Medical ranked first in Hong Kong for ICL surgeries in 2025, marking the third consecutive year of industry leadership [1] Group 2 - The company has incurred significant professional fees exceeding HKD 15 million due to ongoing allegations against former directors, which have created a substantial financial burden that could have been allocated to business development and shareholder returns [1] - The company is committed to efficiently completing the investigation related to the allegations and expediting the resumption of its shares, allowing management to refocus on executing its long-term strategic priorities [1] - The latest resumption guidelines include directives on investigation and rectification, integrity, internal controls, corporate governance, disclosure, financial reporting, and compliance with specific regulations [2]

1月9日-10日，2026"海上之光"眼视光学与视觉科学学术会议暨第十四届"关爱近视·微笑"学术交流会在 上海盛大召开。华厦眼科凭借在屈光手术领域的持续创新与临床质效，一举斩获多项重量级奖项，成为 本届盛会瞩目的焦点。 华厦眼科医院集团领导张志勇先生，集团业务副总院长、上海大学附属上海和平眼科医院院长郭海科教 授，集团眼屈光手术分委会主任委员、郑州华厦视光眼科医院院长刘苏冰教授，集团学术委员会眼屈光 手术分委会常务副主任委员、屈光学科技术总监刘才远教授，集团眼屈光手术分委会常务副主任委员、 上海大学附属上海和平眼科医院副院长翟爱琴教授，集团眼屈光手术分委会副主任委员、重庆华厦眼科 医院院长汪红教授，集团屈光学科发展部负责人唐敏女士，以及集团旗下全国各院的多位专家代表共同 出席大会。 超7000例新全飞SMILE pro手术 质效双优获官方认证 在新一代机器人全飞秒™新微创手术SMILE pro高质量发展论坛上，华厦眼科以超过7000例的临床实践 成果，获颁"新一代机器人全飞秒™新微创SMILE pro手术高质量发展贡献奖"。该奖项不仅是对手术数 量的肯定，更是对华厦眼科在手术标准化、安全性及术后视觉质量的高度 ...

Group 1 - Core viewpoint: Puri Eye Hospital has seen a continuous increase in stock price, with a 5-day cumulative increase of 5.84% as of January 14, reaching a price of 34.26 yuan per share and a total market capitalization of 5.126 billion yuan [1] - Company overview: Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022. The company provides comprehensive medical services for eye diseases, including diagnosis, treatment, healthcare, and optical services [1] - Revenue composition: The main business revenue is derived from refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), vision projects (13.03%), and other services (1.18%) [1] Group 2 - Shareholder information: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) is among the top ten circulating shareholders of Puri Eye Hospital, having reduced its holdings by 192,500 shares in the third quarter, now holding 2.4 million shares, which is 1.69% of the circulating shares [2] - Fund performance: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has achieved a year-to-date return of 9.61% and a one-year return of 26.99%, ranking 782 out of 8,838 and 4,859 out of 8,089 respectively [2] - Fund manager details: The fund manager, Wan Minyuan, has a tenure of 9 years and 144 days, with a total fund asset size of 5.957 billion yuan and a best return of 149.74% during his tenure [2]

有投资者在互动平台向爱尔眼科提问："中国244小时免签政策后，很多欧美发达国家外国人发现中国就 医成本低还效率高，导致越来越多外国人到中国看病，希望贵公司能抓住机会把握时机扩大公司全球影 响力！作为全国眼科龙头，请问贵公司对此有哪些计划？准备如何扩大艾尔眼科国际医疗部对外国患者 的影响力吸引力？自244免签政策后，贵公司国际医疗部外国患者年或月增长率是多少？营业额相比国 内有没有明显提高？谢谢！" 针对上述提问，爱尔眼科回应称："谢谢您对公司的关注。公司在中心城市的医院设有国际诊疗部或特 需部，提供符合国际标准的服务。中国就医的优势越来越明显，公司将依托品牌规模及国际网络，不断 优化诊疗流程，提高就诊便利性，扩大国际医疗部的影响力。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

中证报中证网讯(记者宋维东)中国证券报记者1月13日从何氏眼科（301103）获悉，何氏眼科日前成为 全国眼科联盟人工智能分联盟成员单位，在智慧医疗与人工智能临床应用领域进一步融入国家级前沿创 新平台，为提升诊疗水平、增强科研创新能力提供了重要支撑。何氏眼科相关负责人对中国证券报记者 表示，公司将以此为契机，依托联盟平台与资源优势，持续深化产学研国际合作，拓展人工智能在各类 眼科疾病筛查中的应用，推动科技创新与产业创新深度融合，让优质眼健康服务惠及更广大基层群众。 当前，人工智能、大数据等前沿技术正推动医疗服务向智能化、精准化、个性化方向发展。为促进眼科 人工智能技术发展、加快相关大模型推广应用，全国眼科联盟人工智能分联盟于2025年1月4日成立。目 前，联盟成员单位已超过百家，依托"伏羲慧眼云平台"大模型的多模态本地训练优势，持续推动优质诊 疗资源下沉，赋能基层眼科服务，让群众在家门口就能享受到优质、高效、便捷的眼健康服务。 作为以创新科技为驱动、聚焦全生命周期眼健康管理的数字眼健康生态产业集团，何氏眼科以构建"智 慧光明城"为愿景，联合辽宁何氏医学院、何氏眼产业集团、眼基因库等机构，形成协同创新矩阵。何 ...

智通财经APP讯，朝聚眼科(02219)发布公告，于2026年1月13日斥资15.9万港元回购6万股。 ...

在深耕国内市场的同时，何氏眼科还积极响应共建"一带一路"倡议，联合辽宁何氏医学院、何氏眼产业 集团等合作伙伴，推动中国眼科防盲技术与经验走向国际。通过人才培养、技术分享与防盲模式建设等 方式，将基于人工智能与大数据的创新筛查技术和管理模式推广至"一带一路"共建国家，助力提升当地 基层眼健康服务能力。 何氏眼科方面表示，将以此次加入全国眼科联盟人工智能分联盟为契机，依托联盟平台与资源优势，持 续深化产学研国际合作，拓展人工智能在各类眼科疾病筛查中的应用，推动科技创新与产业创新深度融 合，让优质眼健康服务惠及更广大基层群众，为健康中国建设和全球眼健康事业贡献力量。 本报讯(记者李勇)《证券日报》记者1月13日从辽宁何氏眼科（301103）医院集团股份有限公司(以下简 称"何氏眼科")获悉，何氏眼科于近日正式成为全国眼科联盟人工智能分联盟成员单位。这也标志着何 氏眼科在智慧医疗与人工智能临床应用领域进一步融入国家级前沿创新平台，为其提升诊疗水平、增强 科研创新能力提供了重要支撑。 为促进眼科人工智能技术发展，加快相关大模型推广应用，全国眼科联盟人工智能分联盟于2025年1月4 日正式成立。目前，联盟成员单位已超过百 ...